research use only

Selisistat (EX 527) SIRT1 inhibitor

Name: Selisistat (EX 527)
SKU: S1541
Availability: InStock
Rating: 5 (316 reviews)

Cat.No.S1541

Selisistat (EX 527, SEN0014196) is a potent and selective SIRT1 inhibitor with IC50 of 38 nM in a cell-free assay, and it exhibits >200-fold selectivity against SIRT2 and SIRT3. This compound is in Phase 2.

Chemical Structure

Molecular Weight: 248.71

Jump to Mechanism of Action Cell Culture & Working Concentration Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.78%

99.78

Related Targets	Epigenetic Reader Domain HDAC JAK Histone Methyltransferase AMPK PKC PARP HIF Histone Acetyltransferase Aurora Kinase PRMT Histone Demethylase EZH1/2 DNA Methyltransferase Pim LSD1 MLL JMJD G9a/GLP NSD FTO MicroRNA PAD SETD SMYD DOT1 COMT WDR5 HNMT SAM MTase
Related Products	SRT1720 HCl Sirtinol 3-TYP AGK2 OSS_128167 SRT2104 (GSK2245840) SirReal2 Thiomyristoyl Salvianolic acid B SRT2183 UBCS039 Salermide SRT3025 HCl AK 7 NRD167 Inauhzin CAY10602 Scopolin SIRT1 Antibody [N11B23] SIRT7 inhibitor 97491 SKLB-11A Tenovin-3 E1231 SIRT2 Antibody [B3E9] Fisetin SirT3 Antibody [P20N5] YK 3-237 2-APQC SRT-1460 SirT5 Antibody [N11M22]

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Platelets	Apoptosis Assay	10/50 μM	10 min	DMSO	increases ROS level in a dose-dependent manner	25829495
HEK 293	Growth Inhibition Assay		24 h		IC50=97.7 ± 8.1 μM	24998427
HeLa	Growth Inhibition Assay		24 h		IC50=37.9 ± 1.8 μM	24998427
HEK 293	Growth Inhibition Assay		48 h		IC50=69.0 ± 0.7 μM	24998427
HeLa	Growth Inhibition Assay		48 h		IC50=8.9 ± 1.9 μM	24998427
RMECs	Apoptosis Assay	10 μM	24 h		attenuates the anti-apoptotic effect of Des-G	24486147
HUVECs	Apoptosis Assay	10 μM	24 h		bolishes the protective effect of resveratrol in cell viability	23358928
K562	Function Assay	0.1-1 μM	2 h		stimulates Nrf2-dependent gene transcription	21196497
INS-1E	Function Assay	1 μm	24 h		prevents resveratrol-induced up-regulation of Glut2, glucokinase,Pdx-1, and Tfam	21163946
MCF-7	Growth Inhibition Assay	0-100 μM	24/48/72 h	DMSO	represses cell proliferation at the concentration ≥100 μM	20371709
NCI-H460	Function Assay	1 μm	6 h	DMSO	produces a concentration-dependent increase in the amount of acetylated p53	16354677
293T	Function assay				Inhibition of human recombinant GST-tagged SIRT1 expressed in 293T cells by Fluor de Lys fluorescence assay, IC50 = 0.038 μM.	21306906
Escherichia coli cells	Function assay				Inhibition of human recombinant SIRT1 expressed in Escherichia coli cells using acetylated Lys side chain amino acids 379-382 (Arg-His-Lys-Lys(Ac)) p53 conjugated with aminomethylcoumarin as substrate by fluorescence assay, IC50 = 0.16 μM.	22931526
BL21 (DE3)	Function assay				Inhibition of full length human SIRT1 expressed in Escherichia coli BL21 (DE3) cells using fluorogenic 7-amino-4-methylcoumarin (AMC)-labeled peptide by fluorescence assay, IC50 = 0.21 μM.	25275824
Namalwa cells	Function assay		3 hrs		Inhibition of SIRT1-mediated endogenous p53 deacetylase activity in human Namalwa cells assessed as concentration required to enhance p53 deacetylation to twice the basal level after 3 hrs by ELISA, INH = 0.6 μM.	25971769
BL21 (DE3)	Function assay				Inhibition of full length human SIRT2 expressed in Escherichia coli BL21 (DE3) cells using fluorogenic 7-amino-4-methylcoumarin (AMC)-labeled peptide by fluorescence assay, IC50 = 1.94 μM.	25275824
Escherichia coli cells	Function assay				Inhibition of human recombinant SIRT2 expressed in Escherichia coli cells using acetylated Lys side chain amino acids 379-382 (Arg-His-Lys-Lys(Ac)) p53 conjugated with aminomethylcoumarin as substrate by fluorescence assay, IC50 = 48.5 μM.	22931526
A673	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
SK-N-MC	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
Hs683	Cell cycle assay		24 to 48 hrs		Cell cycle arrest in human Hs683 cells assessed as accumulation at G1 phase at IC50 after 24 to 48 hrs by propidium iodide staining-based flow cytometry	28475330
HCT116	Function assay	10 uM	8 hrs		Inhibition of SIRT1 in human HCT116 cells assessed as increase in acetylated p53 at 10 uM after 8 hrs by Western blot analysis	22642300
NCI-H460	Function assay		6 hrs		Inhibition of SIRT-2 in human NCI-H460 cells assessed as inhibition of p53 deacetylation after 6 hrs by immunoprecipitation/immunoblotting analysis, IC50 = 1 μM.	ChEMBL
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight	248.71	Formula	C₁₃H₁₃ClN₂O	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	49843-98-3	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	SEN0014196			Smiles	C1CC(C2=C(C1)C3=C(N2)C=CC(=C3)Cl)C(=O)N

Solubility

In vitro
Batch:

DMSO : 300 mg/mL (1206.22 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 30 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.000mg/ml (8.04mM)	Taking the 1 mL working solution as an example, add 50 μL of 40 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.000mg/ml (12.06mM)	Taking the 1 mL working solution as an example, add 50 μL of 60 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.000mg/ml (12.06mM)	Taking the 1 mL working solution as an example, add 50 μL of 60 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Features	Greater potency, specificity, stability, and lower toxicity than other inhibitors of SIRT1 catalytic activity identified to date.
Targets/IC₅₀/Ki	SIRT1 ^[1] (Cell-free assay) 38 nM
In vitro	Selisistat (EX 527) exhibits a potently inhibitory effect against SIRT1 deacetylase activity in a concentration-dependent manner with an IC50 of 38 nM, and displays much lower activity against SIRT2 and SIRT3 with IC50 values of 19.6 μM and 48.7 μM, respectively. It does not inhibit SIRT4-7 and class I/II HDAC activity at concentrations up to 100 μM. This compound alone (1 μM) has no detectable effect on the acetylation of p53 lysine 382 in NCI-H460 cells, but significantly increases the amount of acetylated p53 in NCI-H460 cells, human mammary epithelial cells, U-2 OS and MCF-7 cells subjected to genotoxic agents Hydrogen peroxide, which is more effective than that caused by Nicotinamide (5 mM). Surprisingly, it does not result in detectable effects on p53-controled gene expression, cell survival, or cell proliferation. ^[1] It causes a 90% increase in cell number of HCT116 cells after 7 days in the condition of 0.1% serum but not 10% serum, suggesting that SIRT1 is a significant regulator of cell proliferation during growth factor deprivation conditions. ^[2] Additionally, it abrogates resveratrol effects on glucose responses, and prevents resveratrol-induced up-regulation of Glut2, glucokinase, Pdx-1, and Tfam in INS-1E Cells, due to the opposite effect of EX 527 and resveratrol on SIRT1 deacetylase activity. ^[3]
Kinase Assay	Inhibition of GST-SIRT1 deacetylase activity
Kinase Assay	293T cells are transiently transfected with GST-tagged human SIRT1 in the pDEST27 Gateway vector using FuGENE-6. After 48 hours, the cells are lysed with 50 mM Tris, pH 8.0, 120 mM NaCl, 1 mM EDTA, and 0.5% Nonidet P-40, supplemented with Complete Mini protease inhibitor cocktail tablets. GST-SIRT1 is purified from lysates and washed extensively in the above buffer. The deacetylation assay is performed with approximately 30 ng of GST-SIRT1 in the presence of Selisistat (EX 527) (48 pM to 100 μM). Deacetylation is measured using the Fluor de Lys kit using a fluorogenic peptide encompassing residues 379 to 382 of p53, acetylated on lysine 382. The acetylated lysine residue is coupled to an aminomethylcoumarin moiety. The peptide is deacetylated by SIRT1, followed by the addition of a proteolytic developer that releases the fluorescent aminomethylcoumarin. Briefly, enzyme preparations are incubated with 170 μM NAD⁺ and 100 μM p53 fluorogenic peptide for 45 minutes at 37 °C followed by incubation in developer for 15 minutes at 37 °C. Fluorescence is measured by excitation at 360 nm and emission at 460 nm and enzymatic activity is expressed in relative fluorescence units.
In vivo	Administration of Selisistat (EX 527; ~10 μg) to rats increases hypothalamic acetyl-p53 levels by inhibiting hypothalamic SIRT1 activity. Co-administration of this compound with ghrelin markedly blunts the orexigenic action of ghrelin by decreasing the pAMPK levels, increasing the ACC levels, and abolishing the higher expression of the transcription factors FoxO1, pCREB, and Bsx and the neuropeptides NPY and AgRP in the hypothalamic arcuate nucleus. ^[4]
References	[1] https://pubmed.ncbi.nlm.nih.gov/16354677/ [2] https://pubmed.ncbi.nlm.nih.gov/19433578/ [3] https://pubmed.ncbi.nlm.nih.gov/21163946/ [4] https://pubmed.ncbi.nlm.nih.gov/21386086/

Applications

Methods	Biomarkers	PMID
Western blot	GRP78 / FASL / Bcl-2 / LC3 Ac-H3K9 / Fibronectin / Collagen 1 / α-SMA PCNA / Cyclin D1 / Cyclin E pEGFR / EGFR / pPDGFRβ / PDGFRβ pSTAT3 / STAT3 p27 FOXO3a / SIRT1 / Ac-p53 / p16(INK4a)	29312612
Immunofluorescence	p-p38	26824501
Growth inhibition assay	Cell viability	24484175

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01485965	Completed	Huntington''s Disease	Siena Biotech S.p.A.	November 2011	Phase 1
NCT01521832	Completed	Huntington''s Disease	Siena Biotech S.p.A.	October 2009	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
what is the extinction coefficient of it?

Answer:
Its extinction coefficient is 1421.650635.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):